The medical device industry as a whole is under fire. Pricing pressures, the ongoing European recession, and tough competition have all come together to hit revenues at leading device makers. Medtronic (NYSE:MDT) hasn't been immune to those damages as the largest pure medical device maker, and its spine business -- its second-largest segment by sales -- has seen revenue fall 5% over the last nine months as a result.
What's Medtronic's response? The company plans to cut 230 jobs at its spine business and slash costs by 5% in order to compensate for the falling sales. With other companies in the industry also seeing spine revenue lagging -- Stryker's (NYSE:SYK) own spine sales fell 4% in 2012 -- will this measure be enough? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss this question and more in the video below.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Mazor Robotics Fell 10.8% in December
Shares fall by double-digits during a quiet month for the robotic surgery upstart. Is there something to worry about, or is the pullback just market noise?
How Safe Is Medtronic's Dividend?
The medical device manufacturer has a long history of rising dividends, but can its growth continue?
5 Dividend Aristocrats With the Fastest-Growing Dividends
The best kind of dividend stocks: long track records of dividend hikes -- and huge dividend increases.